<DOC>
	<DOC>NCT01087788</DOC>
	<brief_summary>Phase 3, multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of Certolizumab Pegol (CZP) in subjects with adult onset active and progressive Psoriatic Arthritis (PsA).</brief_summary>
	<brief_title>Certolizumab Pegol in Subjects With Adult Onset Active and Progressive Psoriatic Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Psoriatic</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<criteria>Diagnosis of adultonset Psoriatic Arthritis (PsA) of at least 6 months' duration as defined by the Classification Criteria for Psoriatic Arthritis (CASPAR criteria) Active Psoriatic Skin Lesions or a documented history of Psoriasis Active Arthritis with ≥ 3 tender joints at Screening and Baseline, ≥ 3 swollen joints at Screening and Baseline and fulfilling at least 1 of the following 2 criteria during the Screening Period: 1. Erythrocyte Sedimentation Rate (ESR) (Westergren) ≥ 28 mm/hour 2. Creactive protein (CRP) &gt; Upper Limit Normal (ULN) Failure to 1 or more treatment with DiseaseModifying AntiRheumatic Drugs (DMARDs) Diagnosis of any other inflammatory Arthritis or known diagnosis of Fibromyalgia Exposure to more than 1 Tumor Necrosis Factor α (TNFα) antagonist or to more than 2 previous biological response modifiers for PsA or Psoriasis Any nonbiological systemic treatment of Psoriasis; phototherapy; topical agents History of chronic or recurrent infections High risk of infection Live vaccination within the 8 weeks prior to Baseline Concurrent malignancy or a history of malignancy Class III or IV congestive Heart Failure New York Heart Association (NYHA) Demyelinating disease of the central nervous system Clinically significant laboratory abnormalities</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Certolizumab Pegol</keyword>
	<keyword>Cimzia</keyword>
</DOC>